Andrew Bowser

News

NHL: As a second-line treatment in phase 3 trial, tisa-cel disappoints

Author:: Andrew Bowser

Publish date: December 15, 2021

In this phase 3 BELINDA study, CAR T-cell therapy did not prolong event-free survival as a second-line treatment of aggressive non-Hodgkin lymphoma...

News

For leukemias, COVID-19 death risks tied to poor prognoses, ICU deferrals

Author:: Andrew Bowser

Publish date: December 11, 2021

COVID-19 death risks for acute leukemias were driven by poor physician-assessed prognoses and opting out of recommended ICU care.

News

Beta-thalassemia gene therapy achieves lasting transfusion independence

Author:: Andrew Bowser

Publish date: December 11, 2021

“Seeing the restoration of iron metabolism, it really takes us a step closer to really thinking the term ‘cure’ might truly apply.”

News

Response endures in cemiplimab-treated patients with cutaneous SCC

Author:: Andrew Bowser

Publish date: June 14, 2019

MILAN – Time to response was “quite rapid” at a median of 1.9 months in both groups.

News

E-cigarettes beat nicotine patch for smoking cessation

Author:: Andrew Bowser

Publish date: February 13, 2019

The findings contrast with those of earlier studies, which showed a lesser effect of e-cigarettes as a stop-smoking strategy.